About US
Contact us
-
PHEXTOUR Pharma Excipients Application Technology (Great China) Tour Seminar--TaipeiFor the sake of promoting the communication between Taiwan Pharmaceutical companied and excipients company from mainland and oversea; and encourage pharmaceutical companiesto make good use of advanc2014/4/4
-
Erytech gets FDA orphan drug status for ERY-ASP in acute myeloid leukaemiaFrench biopharmaceutical firm Erytech Pharma has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead product GRASPA/ERY-ASP for treatment of acute myeloi2014/4/4
-
European Commission approves Bayer's Adempas to treat two forms of pulmonary hypertensionThe European Commission has approved Bayer's Adempas (riociguat) for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in the European Un2014/4/4
-
Stallergenes obtains US FDA approval for pollen allergy drug OralairFrance-based Stallergenes has secured US Food and Drug Administration (FDA) approval for its immunotherapy tablet Oralair for treatment of grass pollen-induced allergic rhinitis with or without conjun2014/4/3
-
Dainippon's schizophrenia drug Latuda obtains European approvalThe European Commission (EC) has granted marketing authorisation for Japanese pharmaceutical firm Dainippon Sumitomo Pharma's (DSP's) once-daily oral Latuda (lurasidone) for treatment of schizophrenia2014/4/3
-
Roche's subcutaneous formulation of lymphoma drug MabThera gets approval in EuropeThe European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This2014/4/2
-
GSK Announces New Strategic Investments in Africa to Increase Access to Medicines, Build Capacity and Deliver Sustainable GrowthYesterday (31 March 2014), GSK announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. Speaking at the 5th EU2014/4/2
-
AstraZeneca and MRC Enter Strategic Collaboration to Create New Centre for Early Drug Discovery in Cambridge, UKAstraZeneca and the Medical Research Council (MRC) have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creati2014/4/1
-
US FDA accepts Avanir's NDA for AVP-825 to treat migrainesThe US Food and Drug Administration (FDA) has accepted Avanir Pharmaceuticals' new drug application (NDA) of its breath-powered investigational drug-device combination product AVP-825 for the acute tr2014/4/1
-
EMA validates Gilead’s marketing application for hepatitis C combination drugThe European Medicines Agency (EMA) has fully validated Gilead Sciences' marketing authorisation application (MAA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90mg a2014/3/31